
FDA warns of adverse reactions to naltrexone
The FDA said patients should monitor the injection site.
The Food and Drug Administration is
The FDA said patients should monitor the injection site and contact a physician if they develop pain, swelling, tenderness, induration, bruising, pruritus, or redness that does not improve or worsens within two weeks.
To see more Daily News articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.




















































































































































